Passage Bio Inc Net Assets
Passage Bio Inc net assets. Based on the latest financial reports, Passage Bio Inc (PASG) has net assets worth $4.46 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.18 Million) and total liabilities ($20.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PASG year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.46 Million |
| % of Total Assets | 17.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | -94.11% |
| 10-Year Change | N/A |
| Growth Volatility | 47.5 |
Net Assets of Passage Bio Inc (2018–2025)
Net assets of Passage Bio Inc from 2018 to 2025. This chart illustrates how Passage Bio Inc's net assets have evolved over time, based on quarterly financial data. See Passage Bio Inc (PASG) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Passage Bio Inc (2018–2025)
The table below shows the annual net assets of Passage Bio Inc from 2018 to 2025. For live market cap and overall valuation, see Passage Bio Inc (PASG) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $18.75 Million | -69.39% |
| 2024-12-31 | $61.26 Million | -44.95% |
| 2023-12-31 | $111.28 Million | -44.74% |
| 2022-12-31 | $201.37 Million | -36.81% |
| 2021-12-31 | $318.66 Million | +4.58% |
| 2020-12-31 | $304.71 Million | +74.77% |
| 2019-12-31 | $174.35 Million | +1532.28% |
| 2018-12-31 | $-12.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Passage Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69172800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Passage Bio Inc Net Assets Breakdown (December 2025)
Passage Bio Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $723.51 Million | 3857.70% |
| Total Equity | $18.75 Million | 100.00% |
Passage Bio Inc Competitors by Market Cap
The table below lists competitors of Passage Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WIN Metals Ltd
AU:WIN
|
$10.94 Million |
|
Thunderbird Resources Ltd
AU:THB
|
$10.95 Million |
|
Nusantara Almazia
JK:NZIA
|
$10.95 Million |
|
GreenOak Spain Holdings SOCIMI S.A.
MC:YGO2
|
$10.95 Million |
|
Ben Tre Pharmaceutical JSC
VN:DBT
|
$10.93 Million |
|
Vroom, Inc.
NASDAQ:VRMMQ
|
$10.93 Million |
|
Seyitler Kimya Sanayi AS
IS:SEYKM
|
$10.93 Million |
|
Trailbreaker Resources Ltd
V:TBK
|
$10.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Passage Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 61,261,000 to 18,755,000, a change of -42,506,000 (-69.4%).
- Net loss of 45,522,000 reduced equity.
- Share repurchases of 23,000 reduced equity.
- Other comprehensive income decreased equity by 8,000.
- Other factors increased equity by 3,047,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.52 Million | -242.72% |
| Share Repurchases | $23.00K | -0.12% |
| Other Comprehensive Income | $-8.00K | -0.04% |
| Other Changes | $3.05 Million | +16.25% |
| Total Change | $- | -69.39% |
Book Value vs Market Value Analysis
This analysis compares Passage Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-10.16 | $3.40 | x |
| 2019-12-31 | $145.52 | $3.40 | x |
| 2020-12-31 | $133.60 | $3.40 | x |
| 2021-12-31 | $119.47 | $3.40 | x |
| 2022-12-31 | $73.99 | $3.40 | x |
| 2023-12-31 | $40.66 | $3.40 | x |
| 2024-12-31 | $20.28 | $3.40 | x |
| 2025-12-31 | $5.91 | $3.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Passage Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -242.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.32x
- Recent ROE (-242.72%) is below the historical average (-78.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.55 Million |
| 2019 | -26.17% | 0.00% | 0.00x | 1.02x | $-63.07 Million |
| 2020 | -36.83% | 0.00% | 0.00x | 1.08x | $-142.70 Million |
| 2021 | -58.18% | 0.00% | 0.00x | 1.11x | $-217.25 Million |
| 2022 | -67.60% | 0.00% | 0.00x | 1.21x | $-156.26 Million |
| 2023 | -91.71% | 0.00% | 0.00x | 1.35x | $-113.19 Million |
| 2024 | -105.72% | 0.00% | 0.00x | 1.67x | $-70.89 Million |
| 2025 | -242.72% | 0.00% | 0.00x | 3.32x | $-47.40 Million |
Industry Comparison
This section compares Passage Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Passage Bio Inc (PASG) | $4.46 Million | 0.00% | 4.65x | $10.94 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops P… Read more